INOVIQ Ltd

ASX:IIQ Stock Report

Market Cap: AU$58.6m

INOVIQ Future Growth

Future criteria checks 2/6

INOVIQ is forecast to grow earnings and revenue by 26% and 70.9% per annum respectively while EPS is expected to grow by 32.1% per annum.

Key information

26.0%

Earnings growth rate

32.1%

EPS growth rate

Healthcare earnings growth24.1%
Revenue growth rate70.9%
Future return on equityn/a
Analyst coverage

Low

Last updated17 Dec 2024

Recent future growth updates

Recent updates

We Think INOVIQ (ASX:IIQ) Can Afford To Drive Business Growth

Apr 22
We Think INOVIQ (ASX:IIQ) Can Afford To Drive Business Growth

A Look At The Intrinsic Value Of INOVIQ Ltd (ASX:IIQ)

Mar 01
A Look At The Intrinsic Value Of INOVIQ Ltd (ASX:IIQ)

We Think Shareholders May Want To Consider A Review Of INOVIQ Ltd's (ASX:IIQ) CEO Compensation Package

Nov 22
We Think Shareholders May Want To Consider A Review Of INOVIQ Ltd's (ASX:IIQ) CEO Compensation Package

Companies Like INOVIQ (ASX:IIQ) Are In A Position To Invest In Growth

Jun 21
Companies Like INOVIQ (ASX:IIQ) Are In A Position To Invest In Growth

Companies Like INOVIQ (ASX:IIQ) Are In A Position To Invest In Growth

Feb 16
Companies Like INOVIQ (ASX:IIQ) Are In A Position To Invest In Growth

INOVIQ (ASX:IIQ) Is In A Good Position To Deliver On Growth Plans

Sep 28
INOVIQ (ASX:IIQ) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That INOVIQ (ASX:IIQ) Will Use Its Cash Wisely

Jun 08
We're Hopeful That INOVIQ (ASX:IIQ) Will Use Its Cash Wisely

We're Keeping An Eye On INOVIQ's (ASX:IIQ) Cash Burn Rate

Jan 28
We're Keeping An Eye On INOVIQ's (ASX:IIQ) Cash Burn Rate

Are Insiders Selling BARD1 Life Sciences Limited (ASX:BD1) Stock?

Mar 02
Are Insiders Selling BARD1 Life Sciences Limited (ASX:BD1) Stock?

Don't Ignore The Fact That This Insider Just Sold Some Shares In BARD1 Life Sciences Limited (ASX:BD1)

Mar 02
Don't Ignore The Fact That This Insider Just Sold Some Shares In BARD1 Life Sciences Limited (ASX:BD1)

BARD1 Life Sciences (ASX:BD1) Is In A Good Position To Deliver On Growth Plans

Dec 28
BARD1 Life Sciences (ASX:BD1) Is In A Good Position To Deliver On Growth Plans

Earnings and Revenue Growth Forecasts

ASX:IIQ - Analysts future estimates and past financials data (AUD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/202715-2-2-11
6/30/20268-6-5-51
6/30/20252-9-8-81
6/30/20242-7-4-4N/A
3/31/20242-7-5-5N/A
12/31/20232-7-6-5N/A
9/30/20232-8-6-6N/A
6/30/20232-9-7-7N/A
3/31/20232-15-7-6N/A
12/31/20222-21-6-6N/A
9/30/20222-20-6-6N/A
6/30/20222-18-7-6N/A
3/31/20222-14-6-6N/A
12/31/20211-11-6-5N/A
9/30/20211-11-6-5N/A
6/30/20211-11-6-5N/A
3/31/20211-8-6-5N/A
12/31/20201-5-5-5N/A
9/30/20201-4-4-4N/A
6/30/20201-3-3-3N/A
3/31/20201-3-2-2N/A
12/31/20190-2-2-2N/A
9/30/20191-2-2-2N/A
6/30/20191-2-2-2N/A
3/31/20190-2-2-2N/A
12/31/20180-2-2-2N/A
9/30/20180-2-2-2N/A
6/30/20180-2-2-2N/A
3/31/20180-2N/A-2N/A
12/31/20170-2N/A-2N/A
9/30/20170-2N/A-2N/A
6/30/20170-3N/A-2N/A
6/30/2016N/A-6N/A0N/A
12/31/2015N/A0N/A0N/A
12/31/2014N/A0N/A0N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IIQ is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IIQ is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IIQ is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IIQ's revenue (70.9% per year) is forecast to grow faster than the Australian market (5.9% per year).

High Growth Revenue: IIQ's revenue (70.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if IIQ's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 15:07
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

INOVIQ Ltd is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Chris KallosMST Financial Services Pty Limited